Posttransplant anemia: the role of sirolimus.
Posttransplant anemia is a common problem that may hinder patients' quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
Fishbane
Steven
S
Division of Nephrology, Winthrop-University Hospital, Mineola, New York 11501, USA. sfishbane@winthrop.org
Cohen
David J
DJ
Coyne
Daniel W
DW
Djamali
Arjang
A
Singh
Ajay K
AK
Wish
Jay B
JB
D000740:Anemia / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents; D016030:Kidney Transplantation / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D020123:Sirolimus